Zobrazeno 1 - 4
of 4
pro vyhledávání: '"F J, Cohen"'
Autor:
M, Dowsett, N J, Bundred, A, Decensi, R C, Sainsbury, Y, Lu, M J, Hills, F J, Cohen, P, Veronesi, M E, O'Brien, T, Scott, D B, Muchmore
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 10(9)
Raloxifene is a selective estrogen receptor (ER) modulator approved for prevention and treatment of postmenopausal osteoporosis. This is an exploratory study of raloxifene in primary breast cancer patients.Postmenopausal women (50-80 years of age), w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c48aeb5484097e855d2ddc18277bbb65
https://pubmed.ncbi.nlm.nih.gov/11535548
https://pubmed.ncbi.nlm.nih.gov/11535548
Autor:
B, Ettinger, D M, Black, B H, Mitlak, R K, Knickerbocker, T, Nickelsen, H K, Genant, C, Christiansen, P D, Delmas, J R, Zanchetta, J, Stakkestad, C C, Glüer, K, Krueger, F J, Cohen, S, Eckert, K E, Ensrud, L V, Avioli, P, Lips, S R, Cummings
Publikováno v:
JAMA. 282(7)
Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known.To determine the effect of raloxifene therapy on risk of vertebral and non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0d833a7cbb8ad03a6a892a5add2b112a
https://pubmed.ncbi.nlm.nih.gov/10807376
https://pubmed.ncbi.nlm.nih.gov/10807376
Publikováno v:
Menopause (New York, N.Y.). 6(3)
To determine the endometrial effects of raloxifene 60 mg/day in postmenopausal women as assessed by vaginal bleeding and endometrial thickness.Data from 1157 postmenopausal women were analyzed from a database consisting of four independent, double-bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6688cf19365a09f12c4b6c5009869b02
https://pubmed.ncbi.nlm.nih.gov/10486785
https://pubmed.ncbi.nlm.nih.gov/10486785
Publikováno v:
Cancer research. 48(23)
Recent evidence indicates that the antiestrogen tamoxifen (TAM) may inhibit breast cancer cell proliferation, at least in part, through suppression of the polyamine (PA) pathway. To directly test this hypothesis, we evaluated the effect of TAM admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::35bfb4fdfbd738c5b6887b427a0f32be
https://pubmed.ncbi.nlm.nih.gov/3180091
https://pubmed.ncbi.nlm.nih.gov/3180091